BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rambaldi A, Gritti G, Micò MC, Frigeni M, Borleri G, Salvi A, Landi F, Pavoni C, Sonzogni A, Gianatti A, Binda F, Fagiuoli S, Di Marco F, Lorini L, Remuzzi G, Whitaker S, Demopulos G. Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab.Immunobiology. 2020;225:152001. [PMID: 32943233 DOI: 10.1016/j.imbio.2020.152001] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 20.5] [Reference Citation Analysis]
Number Citing Articles
1 Agostinis C, Mangogna A, Balduit A, Aghamajidi A, Ricci G, Kishore U, Bulla R. COVID-19, Pre-Eclampsia, and Complement System. Front Immunol 2021;12:775168. [PMID: 34868042 DOI: 10.3389/fimmu.2021.775168] [Reference Citation Analysis]
2 Norsa L, Bonaffini PA, Caldato M, Bonifacio C, Sonzogni A, Indriolo A, Valle C, Furfaro F, Bonanomi A, Franco PN, Gori M, Smania V, Scaramella L, Forzenigo L, Vecchi M, Solbiati M, Costantino G, Danese S, D'Antiga L, Sironi S, Elli L. Intestinal ischemic manifestations of SARS-CoV-2: Results from the ABDOCOVID multicentre study. World J Gastroenterol 2021; 27(32): 5448-5459 [PMID: 34539144 DOI: 10.3748/wjg.v27.i32.5448] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Bekassy Z, Lopatko Fagerström I, Bader M, Karpman D. Crosstalk between the renin-angiotensin, complement and kallikrein-kinin systems in inflammation. Nat Rev Immunol 2021. [PMID: 34759348 DOI: 10.1038/s41577-021-00634-8] [Reference Citation Analysis]
4 Maixnerova D, El Mehdi D, Rizk DV, Zhang H, Tesar V. New Treatment Strategies for IgA Nephropathy: Targeting Plasma Cells as the Main Source of Pathogenic Antibodies. J Clin Med 2022;11:2810. [PMID: 35628935 DOI: 10.3390/jcm11102810] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Nilsson B, Persson B, Eriksson O, Fromell K, Hultström M, Frithiof R, Lipcsey M, Huber-Lang M, Ekdahl KN. How the Innate Immune System of the Blood Contributes to Systemic Pathology in COVID-19-Induced ARDS and Provides Potential Targets for Treatment. Front Immunol 2022;13:840137. [PMID: 35350780 DOI: 10.3389/fimmu.2022.840137] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Gavriilaki E, Eftychidis I, Papassotiriou I. Update on endothelial dysfunction in COVID-19: severe disease, long COVID-19 and pediatric characteristics. Journal of Laboratory Medicine 2021;45:293-302. [DOI: 10.1515/labmed-2021-0134] [Reference Citation Analysis]
7 Mondello C, Roccuzzo S, Malfa O, Sapienza D, Gualniera P, Ventura Spagnolo E, Di Nunno N, Salerno M, Pomara C, Asmundo A. Pathological Findings in COVID-19 as a Tool to Define SARS-CoV-2 Pathogenesis. A Systematic Review. Front Pharmacol 2021;12:614586. [PMID: 33867981 DOI: 10.3389/fphar.2021.614586] [Reference Citation Analysis]
8 Kurtovic L, Beeson JG. Complement Factors in COVID-19 Therapeutics and Vaccines. Trends Immunol 2021;42:94-103. [PMID: 33402318 DOI: 10.1016/j.it.2020.12.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
9 Diorio C, McNerney KO, Lambert M, Paessler M, Anderson EM, Henrickson SE, Chase J, Liebling EJ, Burudpakdee C, Lee JH, Balamuth FB, Blatz AM, Chiotos K, Fitzgerald JC, Giglia TM, Gollomp K, Odom John AR, Jasen C, Leng T, Petrosa W, Vella LA, Witmer C, Sullivan KE, Laskin BL, Hensley SE, Bassiri H, Behrens EM, Teachey DT. Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations. Blood Adv 2020;4:6051-63. [PMID: 33290544 DOI: 10.1182/bloodadvances.2020003471] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 14.5] [Reference Citation Analysis]
10 Yasmin H, Saha S, Butt MT, Modi RK, George AJT, Kishore U. SARS-CoV-2: Pathogenic Mechanisms and Host Immune Response. Adv Exp Med Biol 2021;1313:99-134. [PMID: 34661893 DOI: 10.1007/978-3-030-67452-6_6] [Reference Citation Analysis]
11 Paludan SR, Mogensen TH. Innate immunological pathways in COVID-19 pathogenesis. Sci Immunol 2022;7:eabm5505. [PMID: 34995097 DOI: 10.1126/sciimmunol.abm5505] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 22.0] [Reference Citation Analysis]
12 Kisserli A, Schneider N, Audonnet S, Tabary T, Goury A, Cousson J, Mahmoudi R, Bani-Sadr F, Kanagaratnam L, Jolly D, Cohen JH. Acquired decrease of the C3b/C4b receptor (CR1, CD35) and increased C4d deposits on erythrocytes from ICU COVID-19 patients. Immunobiology 2021;226:152093. [PMID: 34022670 DOI: 10.1016/j.imbio.2021.152093] [Reference Citation Analysis]
13 Gavriilaki E, Ho VT, Schwaeble W, Dudler T, Daha M, Fujita T, Jodele S. Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy. Exp Hematol Oncol 2021;10:57. [PMID: 34924021 DOI: 10.1186/s40164-021-00249-8] [Reference Citation Analysis]
14 Brogna B, Bignardi E, Brogna C, Volpe M, Lombardi G, Rosa A, Gagliardi G, Capasso PFM, Gravino E, Maio F, Pane F, Picariello V, Buono M, Colucci L, Musto LA. A Pictorial Review of the Role of Imaging in the Detection, Management, Histopathological Correlations, and Complications of COVID-19 Pneumonia. Diagnostics (Basel) 2021;11:437. [PMID: 33806423 DOI: 10.3390/diagnostics11030437] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
15 Speeckaert MM, Delanghe JR. Letter to the Editor from M. M. Speeckaert et al.: Vitamin D deficiency is associated with higher hospitalization risk from COVID-19: A retrospective case-control study. J Clin Endocrinol Metab 2021:dgab606. [PMID: 34529788 DOI: 10.1210/clinem/dgab606] [Reference Citation Analysis]
16 Otieno SB, Altahan A, Kaweeta F, Karri S, Alnoor F, Johnson R. Severe Hemolysis in a COVID-19 Patient with Paroxysmal Nocturnal Hemoglobinuria. Case Rep Hematol 2021;2021:6619177. [PMID: 34306774 DOI: 10.1155/2021/6619177] [Reference Citation Analysis]
17 Norsa L. Reply. Gastroenterology 2021;160:2192. [PMID: 33484692 DOI: 10.1053/j.gastro.2021.01.197] [Reference Citation Analysis]
18 Noris M. The case of complement inhibitors. Adv Biol Regul 2021;81:100822. [PMID: 34454870 DOI: 10.1016/j.jbior.2021.100822] [Reference Citation Analysis]
19 Ai J, Hong W, Wu M, Wei X. Pulmonary vascular system: A vulnerable target for COVID-19. MedComm (2020) 2021. [PMID: 34909758 DOI: 10.1002/mco2.94] [Reference Citation Analysis]
20 Mortazavi-Jahromi SS, Aslani M. Dysregulated miRNAs network in the critical COVID-19: An important clue for uncontrolled immunothrombosis/thromboinflammation. Int Immunopharmacol 2022;110:109040. [PMID: 35839566 DOI: 10.1016/j.intimp.2022.109040] [Reference Citation Analysis]
21 Świerzko AS, Cedzyński M. The Influence of the Lectin Pathway of Complement Activation on Infections of the Respiratory System. Front Immunol 2020;11:585243. [PMID: 33193407 DOI: 10.3389/fimmu.2020.585243] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
22 Annane D, Heming N, Grimaldi-Bensouda L, Frémeaux-Bacchi V, Vigan M, Roux AL, Marchal A, Michelon H, Rottman M, Moine P; Garches COVID 19 Collaborative Group. Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study. EClinicalMedicine 2020;28:100590. [PMID: 33173853 DOI: 10.1016/j.eclinm.2020.100590] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 19.0] [Reference Citation Analysis]
23 Belcher JD, Nguyen J, Chen C, Abdulla F, Conglin R, Ivy ZK, Cummings J, Dudler T, Vercellotti GM. MASP-2 and MASP-3 inhibitors block complement activation, inflammation, and microvascular stasis in a murine model of vaso-occlusion in sickle cell disease. Transl Res 2022:S1931-5244(22)00152-9. [PMID: 35878790 DOI: 10.1016/j.trsl.2022.06.018] [Reference Citation Analysis]
24 Haybar H, Maniati M, Saki N, Zayeri ZD. COVID-19: imbalance of multiple systems during infection and importance of therapeutic choice and dosing of cardiac and anti-coagulant therapies. Mol Biol Rep 2021;48:2917-28. [PMID: 33837899 DOI: 10.1007/s11033-021-06333-w] [Reference Citation Analysis]
25 Peng M, Yan QH, Gao Y, Zhang Z, Zhang Y, Wang YF, Wu HN. Correlation between circulating endothelial cell level and acute respiratory distress syndrome in postoperative patients. World J Clin Cases 2021; 9(32): 9731-9740 [PMID: 34877312 DOI: 10.12998/wjcc.v9.i32.9731] [Reference Citation Analysis]
26 Bumiller-Bini V, de Freitas Oliveira-Toré C, Carvalho TM, Kretzschmar GC, Gonçalves LB, Alencar NM, Gasparetto Filho MA, Beltrame MH, Winter Boldt AB. MASPs at the crossroad between the complement and the coagulation cascades - the case for COVID-19. Genet Mol Biol 2021;44:e20200199. [PMID: 33729332 DOI: 10.1590/1678-4685-GMB-2020-0199] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Jalink M, de Boer ECW, Evers D, Havinga MQ, Vos JMI, Zeerleder S, de Haas M, Jongerius I. Halting targeted and collateral damage to red blood cells by the complement system. Semin Immunopathol 2021. [PMID: 34191092 DOI: 10.1007/s00281-021-00859-8] [Reference Citation Analysis]
28 Satyam A, Hisada R, Bhargava R, Tsokos MG, Tsokos GC. Intertwined pathways of complement activation command the pathogenesis of lupus nephritis. Transl Res 2022:S1931-5244(22)00048-2. [PMID: 35296451 DOI: 10.1016/j.trsl.2022.03.005] [Reference Citation Analysis]
29 Perico L, Morigi M, Galbusera M, Pezzotta A, Gastoldi S, Imberti B, Perna A, Ruggenenti P, Donadelli R, Benigni A, Remuzzi G. SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet Aggregation. Front Immunol 2022;13:827146. [DOI: 10.3389/fimmu.2022.827146] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
30 Chen C, Amelia A, Ashdown GW, Mueller I, Coussens AK, Eriksson EM. Risk surveillance and mitigation: autoantibodies as triggers and inhibitors of severe reactions to SARS-CoV-2 infection. Mol Med 2021;27. [DOI: 10.1186/s10020-021-00422-z] [Reference Citation Analysis]
31 Macor P, Durigutto P, Mangogna A, Bussani R, De Maso L, D'Errico S, Zanon M, Pozzi N, Meroni PL, Tedesco F. Multiple-Organ Complement Deposition on Vascular Endothelium in COVID-19 Patients. Biomedicines 2021;9:1003. [PMID: 34440207 DOI: 10.3390/biomedicines9081003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Lim EHT, van Amstel RBE, de Boer VV, van Vught LA, de Bruin S, Brouwer MC, Vlaar APJ, van de Beek D. Complement activation in COVID-19 and targeted therapeutic options: A scoping review. Blood Reviews 2022. [DOI: 10.1016/j.blre.2022.100995] [Reference Citation Analysis]
33 Milone G, Bellofiore C, Leotta S, Milone GA, Cupri A, Duminuco A, Garibaldi B, Palumbo G. Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology. J Clin Med 2022;11:623. [PMID: 35160072 DOI: 10.3390/jcm11030623] [Reference Citation Analysis]
34 Prohászka Z, Merle NS. Editorial: Complement and COVID-19 Disease. Front Immunol 2022;13:960809. [DOI: 10.3389/fimmu.2022.960809] [Reference Citation Analysis]
35 Boudhabhay I, Rabant M, Roumenina LT, Coupry LM, Poillerat V, Marchal A, Frémeaux-Bacchi V, El Karoui K, Monchi M, Pourcine F. Case Report: Adult Post-COVID-19 Multisystem Inflammatory Syndrome and Thrombotic Microangiopathy. Front Immunol 2021;12:680567. [PMID: 34248962 DOI: 10.3389/fimmu.2021.680567] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
36 Yuan C, Li R, Liu G, Pan Y. Potential of Immune-Related Therapy in COVID-19. Front Pharmacol 2020;11:609212. [PMID: 33574756 DOI: 10.3389/fphar.2020.609212] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Zuo Y, Kanthi Y, Knight JS, Kim AHJ. The interplay between neutrophils, complement, and microthrombi in COVID-19. Best Pract Res Clin Rheumatol 2021;35:101661. [PMID: 33526325 DOI: 10.1016/j.berh.2021.101661] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
38 Burwick RM, Dellapiana G, Newman RA, Smithson SD, Naqvi M, Williams J 3rd, Wong MS, Bautista M, Gaden A, Kazani SD, Dunn DA, Ma MH, Mitter S, Monteleone JPR, Ortiz SR, Ghandehari S, Merin N, Zakowski MI, Karumanchi SA. Complement blockade with eculizumab for treatment of severe Coronavirus Disease 2019 in pregnancy: A case series. Am J Reprod Immunol 2022;:e13559. [PMID: 35514201 DOI: 10.1111/aji.13559] [Reference Citation Analysis]
39 Stenmark KR, Frid MG, Gerasimovskaya E, Zhang H, McCarthy MK, Thurman JM, Morrison TE. Mechanisms of SARS-CoV-2-induced lung vascular disease: potential role of complement. Pulm Circ 2021;11:20458940211015799. [PMID: 34046161 DOI: 10.1177/20458940211015799] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
40 Ardissino G, Capone V, Tedeschi S, Porcaro L, Cugno M. Complement System as a New Target for Hematopoietic Stem Cell Transplantation-Related Thrombotic Microangiopathy. Pharmaceuticals (Basel) 2022;15:845. [PMID: 35890144 DOI: 10.3390/ph15070845] [Reference Citation Analysis]
41 Ortiz A. Complement and protection from tissue injury in COVID-19. Clin Kidney J 2020;13:734-8. [PMID: 33123353 DOI: 10.1093/ckj/sfaa196] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Li Q, Chen Z. An update: the emerging evidence of complement involvement in COVID-19. Med Microbiol Immunol. 2021;1-9. [PMID: 33811541 DOI: 10.1007/s00430-021-00704-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Marsteller NL, Fregoso DJ, Morphew TL, Randhawa IS. Immune Response to SARS-CoV-2 in an Asymptomatic Pediatric Allergic Cohort. Antibodies (Basel) 2021;10:22. [PMID: 34199430 DOI: 10.3390/antib10020022] [Reference Citation Analysis]
44 Ram Kumar Pandian S, Arunachalam S, Deepak V, Kunjiappan S, Sundar K. Targeting complement cascade: an alternative strategy for COVID-19. 3 Biotech 2020;10:479. [PMID: 33088671 DOI: 10.1007/s13205-020-02464-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
45 Morajkar RV, Kumar AS, Kunkalekar RK, Vernekar AA. Advances in nanotechnology application in biosafety materials: a crucial response to COVID-19 pandemic. Biosaf Health 2022. [PMID: 35765656 DOI: 10.1016/j.bsheal.2022.06.001] [Reference Citation Analysis]
46 Brain D, Plant-Hately A, Heaton B, Arshad U, David C, Hedrich C, Owen A, Liptrott NJ. Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19. Adv Drug Deliv Rev 2021;178:113848. [PMID: 34182016 DOI: 10.1016/j.addr.2021.113848] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
47 Lynch NJ, Chan ACY, Ali YM, Khatri P, Bamigbola IE, Demopulos G, Paganessi M, Rambaldi A, Schwaeble WJ. Inhibition of the lectin pathway of complement ameliorates hypocomplementemia and restores serum bactericidal activity in patients with severe COVID-19. Clin Transl Med 2022;12:e980. [PMID: 35839316 DOI: 10.1002/ctm2.980] [Reference Citation Analysis]
48 Deravi N, Ahsan E, Fathi M, Hosseini P, Yaghoobpoor S, Lotfi R, Pourbagheri-Sigaroodi A, Bashash D. Complement inhibition: A possible therapeutic approach in the fight against Covid-19. Rev Med Virol 2021;:e2316. [PMID: 34873779 DOI: 10.1002/rmv.2316] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Flude BM, Nannetti G, Mitchell P, Compton N, Richards C, Heurich M, Brancale A, Ferla S, Bassetto M. Targeting the Complement Serine Protease MASP-2 as a Therapeutic Strategy for Coronavirus Infections. Viruses 2021;13:312. [PMID: 33671334 DOI: 10.3390/v13020312] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Li Q, Wang Y, Sun Q, Knopf J, Herrmann M, Lin L, Jiang J, Shao C, Li P, He X, Hua F, Niu Z, Ma C, Zhu Y, Ippolito G, Piacentini M, Estaquier J, Melino S, Weiss FD, Andreano E, Latz E, Schultze JL, Rappuoli R, Mantovani A, Mak TW, Melino G, Shi Y. Immune response in COVID-19: what is next? Cell Death Differ 2022;29:1107-22. [PMID: 35581387 DOI: 10.1038/s41418-022-01015-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Magro C, Nuovo G, Mulvey JJ, Laurence J, Harp J, Crowson AN. The skin as a critical window in unveiling the pathophysiologic principles of COVID-19. Clinics in Dermatology 2021;39:934-65. [DOI: 10.1016/j.clindermatol.2021.07.001] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
52 Macor P, Durigutto P, Mangogna A, Bussani R, D'Errico S, Zanon M, Pozzi N, Meroni P, Tedesco F. Multi-organ complement deposition in COVID-19 patients. medRxiv 2021:2021. [PMID: 33442701 DOI: 10.1101/2021.01.07.21249116] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
53 Asteris PG, Gavriilaki E, Touloumenidou T, Koravou E, Koutra M, Papayanni PG, Pouleres A, Karali V, Lemonis ME, Mamou A, Skentou AD, Papalexandri A, Varelas C, Chatzopoulou F, Chatzidimitriou M, Chatzidimitriou D, Veleni A, Rapti E, Kioumis I, Kaimakamis E, Bitzani M, Boumpas D, Tsantes A, Sotiropoulos D, Papadopoulou A, Kalantzis IG, Vallianatou LA, Armaghani DJ, Cavaleri L, Gandomi AH, Hajihassani M, Hasanipanah M, Koopialipoor M, Lourenço PB, Samui P, Zhou J, Sakellari I, Valsami S, Politou M, Kokoris S, Anagnostopoulos A. Genetic prediction of ICU hospitalization and mortality in COVID‐19 patients using artificial neural networks. J Cellular Molecular Medi. [DOI: 10.1111/jcmm.17098] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
54 Zarubova J, Zhang X, Hoffman T, Hasani-Sadrabadi MM, Li S. Biomaterial-based immunoengineering to fight COVID-19 and infectious diseases. Matter 2021;4:1528-54. [PMID: 33723531 DOI: 10.1016/j.matt.2021.02.025] [Reference Citation Analysis]
55 Bunprakob S, Hemachudha P, Ruchisrisarod C, Supharatpariyakorn T, Hemachudha T. IP-10 and complement activation as friend or foe in COVID-19. Int J Immunopathol Pharmacol 2022;36:039463202210962. [DOI: 10.1177/03946320221096202] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Fernandez-Ruiz R, Paredes JL, Niewold TB. COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease. Transl Res 2021;232:13-36. [PMID: 33352298 DOI: 10.1016/j.trsl.2020.12.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
57 Agostinis C, Balduit A, Mangogna A, Zito G, Romano F, Ricci G, Kishore U, Bulla R. Immunological Basis of the Endometriosis: The Complement System as a Potential Therapeutic Target. Front Immunol 2020;11:599117. [PMID: 33505394 DOI: 10.3389/fimmu.2020.599117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
58 Blasco M, Guillén-Olmos E, Diaz-Ricart M, Palomo M. Complement Mediated Endothelial Damage in Thrombotic Microangiopathies. Front Med (Lausanne) 2022;9:811504. [PMID: 35547236 DOI: 10.3389/fmed.2022.811504] [Reference Citation Analysis]
59 Damiani M, Gandini L, Landi F, Borleri G, Fabretti F, Gritti G, Riva I. Extracorporeal cytokine hemadsorption in severe COVID-19 respiratory failure. Respir Med 2021;185:106477. [PMID: 34102594 DOI: 10.1016/j.rmed.2021.106477] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
60 Zhang Y, Chen Y, Meng Z. Immunomodulation for Severe COVID-19 Pneumonia: The State of the Art.Front Immunol. 2020;11:577442. [PMID: 33240265 DOI: 10.3389/fimmu.2020.577442] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
61 Fodil S, Annane D. Complement Inhibition and COVID-19: The Story so Far. Immunotargets Ther 2021;10:273-84. [PMID: 34345614 DOI: 10.2147/ITT.S284830] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
62 Gianni P, Goldin M, Ngu S, Zafeiropoulos S, Geropoulos G, Giannis D. Complement-mediated microvascular injury and thrombosis in the pathogenesis of severe COVID-19: A review. World J Exp Med 2022; 12(4): 53-67 [DOI: 10.5493/wjem.v12.i4.53] [Reference Citation Analysis]
63 Ng N, Powell CA. Targeting the Complement Cascade in the Pathophysiology of COVID-19 Disease. J Clin Med 2021;10:2188. [PMID: 34069355 DOI: 10.3390/jcm10102188] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
64 Niederreiter J, Eck C, Ries T, Hartmann A, Märkl B, Büttner-Herold M, Amann K, Daniel C. Complement Activation via the Lectin and Alternative Pathway in Patients With Severe COVID-19. Front Immunol 2022;13:835156. [PMID: 35237273 DOI: 10.3389/fimmu.2022.835156] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
65 Ali YM, Ferrari M, Lynch NJ, Yaseen S, Dudler T, Gragerov S, Demopulos G, Heeney JL, Schwaeble WJ. Lectin Pathway Mediates Complement Activation by SARS-CoV-2 Proteins. Front Immunol 2021;12:714511. [PMID: 34290717 DOI: 10.3389/fimmu.2021.714511] [Reference Citation Analysis]
66 Sinkovits G, Mező B, Réti M, Müller V, Iványi Z, Gál J, Gopcsa L, Reményi P, Szathmáry B, Lakatos B, Szlávik J, Bobek I, Prohászka ZZ, Förhécz Z, Csuka D, Hurler L, Kajdácsi E, Cervenak L, Kiszel P, Masszi T, Vályi-Nagy I, Prohászka Z. Complement Overactivation and Consumption Predicts In-Hospital Mortality in SARS-CoV-2 Infection. Front Immunol 2021;12:663187. [PMID: 33841446 DOI: 10.3389/fimmu.2021.663187] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]